Clinical trial · Interventional
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
NCT05540951CI-TRIAL-00060870unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab Plus Chemotherapy | Drug | — | UNRESOLVED |
| VIC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- VIC
- description
- VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
- interventionNames
- Drug: VIC
- type
- ACTIVE_COMPARATOR
- label
- BEV
- description
- Bevacizumab Plus Chemotherapy
- interventionNames
- Drug: Bevacizumab Plus Chemotherapy
Primary outcomes (3)
- measure
- progression-free survival
- timeFrame
- 3 years
- description
- time from first study treatment to the first documented progression disease or death, whichever occurred first
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 and ≤80 years old * Histologically confirmed colorectal adenocarcinoma * Histologically confirmed BRAFV600E mutated and RAS wild-type * Initially unresectable metastatic or local CRC * ECOG performance status of 0-1 and life expectancy ≥3 months * adequate hepatic, renal, and hematologic function Exclusion Criteria: * Previously taken any targeted therapy, chemotherapy, intervention therapy, or radiotherapy for CRC within 6 months * Other cancers (with the exception of cervical cancer in situ and squamous cell carcinoma of the skin) within the previous 5 years.
References
Publications (0)
Data not yet available
No reference posted for this study.